Content · Pharma

AEM Forms for Pharma

HCP and patient engagement with compliance review. Here's how AEM Forms addresses the specific shape of that problem — and what to measure.

Overview

AEM Forms in pharma: the shape of the problem

Pharmaceutical marketing operates under medical, legal and regulatory review, making content reuse and approval workflow central to speed. Against that backdrop, AEM Forms is not a generic tool that happens to be deployable in pharma — its value depends entirely on being configured around the sector's identity models, consent constraints and journey shapes.

Challenges

The pharma problem

  • MLR review cycles slowing content delivery
  • Separate HCP and patient experiences and consent
  • Global brand consistency across markets
  • Adverse event capture obligations

Solution

How AEM Forms addresses it

  • Deploy AEM Forms against the pharma journeys where mlr review cycles slowing content delivery.
  • Adaptive Forms with conditional logic and save-resume — applied to pharma data and journeys.
  • Document generation and communications output — applied to pharma data and journeys.
  • E-signature integration including Adobe Sign — applied to pharma data and journeys.
  • Backend integration via form data models — applied to pharma data and journeys.

Architecture

Solution architecture

A pharma deployment of AEM Forms starts from the sector's constraints — consent scope, identity sources and integration points with systems of record — and works backwards to collection and activation design. The architecture phase produces a design your compliance and engineering teams sign off before configuration begins.

  • Identity and consent model mapped to sector regulation
  • Integration points with core systems defined up front
  • AEM Forms configured against sector journey patterns
  • Measurement framework tied to the KPIs below

KPIs

What success is measured by

Content approval cycle time

HCP engagement depth

Market launch time-to-live

Asset reuse rate

Benefits

What changes

  • Cut abandonment on long enrollment and claims journeys
  • Replace paper and PDF processes with auditable digital flows
  • Meet accessibility obligations without bespoke build
  • A measurement and activation approach aligned to how Pharma actually operates, not a generic template

Frequently asked questions

Is AEM Forms suitable for pharma compliance requirements?

Adobe's platforms carry the certifications and data-governance controls that regulated pharma organizations require, and we design every implementation around your specific regulatory constraints — consent, residency and retention are architecture inputs, not afterthoughts.

Do you have pharma implementation experience?

DWAO delivers across pharma and adjacent sectors globally. We'll gladly walk you through relevant case studies and reference architectures on a call.

How do we measure success for AEM Forms in pharma?

We anchor the implementation to the KPIs that matter in your sector — such as content approval cycle time and hcp engagement depth — and build the measurement for them into the platform from day one.

What does an engagement look like?

Discovery and success definition first, then architecture, implementation and enablement. Most clients start with a short assessment that produces a costed roadmap before committing to delivery.

How long until AEM Forms shows value in pharma?

A first production use case typically ships within a quarter, with the measurement for content approval cycle time built in from day one so impact is visible immediately rather than claimed retrospectively.

Discuss AEM Forms for your pharma organization

Tell us where you are and what you're trying to achieve. A certified consultant from DWAO will come back with a practical next step — not a sales pitch.

  • Adobe Gold Partner with certified specialists
  • Response within one business day
  • Delivery teams across five countries

We only use your details to respond to this enquiry. No spam, no resale.